Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
406,518

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Zacks Equity Research

Inogen (INGN) Announces Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.

Zacks Equity Research

UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions

by Zacks Equity Research

UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.

Zacks Equity Research

PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.

Zacks Equity Research

Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

Zacks Equity Research

QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails

by Zacks Equity Research

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.

Zacks Equity Research

Syneos Health (SYNH) to Launch Serplulimab With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

Zacks Equity Research

Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Zacks Equity Research

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Equity Research

DexCom (DXCM) Announces Solid Preliminary Q4 Revenues

by Zacks Equity Research

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.

Zacks Equity Research

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

by Zacks Equity Research

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

Zacks Equity Research

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.

Zacks Equity Research

Illumina (ILMN), Nashville Biosciences Partner With Amgen

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Zacks Equity Research

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

by Zacks Equity Research

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Zacks Equity Research

Abbott's (ABT) New Launch to Boost Blood Donation Experience

by Zacks Equity Research

Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.

Zacks Equity Research

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.

Zacks Equity Research

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

Zacks Equity Research

Baxter (BAX) Plans to Form Standalone Kidney Care Company

by Zacks Equity Research

Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.

Zacks Equity Research

Teladoc (TDOC) Unveils App to Simplify Whole-Person Care

by Zacks Equity Research

Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?